168 related articles for article (PubMed ID: 6193072)
1. Carcinoembryonic antigen (CEA) and carbohydrate determinant 19-9 (CA 19-9) localization in 121 primary and metastatic ovarian tumors: an immunohistochemical study with the use of monoclonal antibodies.
Charpin C; Bhan AK; Zurawski VR; Scully RE
Int J Gynecol Pathol; 1982; 1(3):231-45. PubMed ID: 6193072
[TBL] [Abstract][Full Text] [Related]
2. Human alveolar macrophage-56 and carcinoembryonic antigen monoclonal antibodies in the differential diagnosis between primary ovarian and metastatic gastrointestinal carcinomas.
Fowler LJ; Maygarden SJ; Novotny DB
Hum Pathol; 1994 Jul; 25(7):666-70. PubMed ID: 8026826
[TBL] [Abstract][Full Text] [Related]
3. Tissue expression of CA 125 in benign and malignant lesions of ovary and fallopian tube: a comparison with CA 19-9 and CEA.
Neunteufel W; Breitenecker G
Gynecol Oncol; 1989 Mar; 32(3):297-302. PubMed ID: 2646183
[TBL] [Abstract][Full Text] [Related]
4. Carcinoembryonic antigen in primary and metastatic ovarian tumors.
Fleuren GJ; Nap M
Gynecol Oncol; 1988 Jul; 30(3):407-15. PubMed ID: 2839395
[TBL] [Abstract][Full Text] [Related]
5. The expression of CEA, CA 19-9 and HMFG antigens in ovarian clear-cell and endometrioid carcinomas.
Helle M; Helin H; Ashorn P; Putkinen EL; Krohn K; Wahlström T
Pathol Res Pract; 1992 Feb; 188(1-2):74-7. PubMed ID: 1594502
[TBL] [Abstract][Full Text] [Related]
6. Improved specificity of the CA 125 enzyme immunoassay for ovarian carcinomas by use of the ratio of CA 125 to carcinoembryonic antigen.
Wu JT; Miya T; Knight JA; Knight DP
Clin Chem; 1988 Sep; 34(9):1853-7. PubMed ID: 2458203
[TBL] [Abstract][Full Text] [Related]
7. [An immunohistochemical study of intestinal mucinous antigens and CEA in ovarian epithelial tumors].
Liu A; Wang M; Li H
Zhonghua Bing Li Xue Za Zhi; 1995 Dec; 24(6):366-8. PubMed ID: 8732094
[TBL] [Abstract][Full Text] [Related]
8. Three novel mouse monoclonal antibodies, OM-A, OM-B, and OM-C, reactive with mucinous type ovarian tumors.
Sakakibara K; Ueda R; Ohta M; Nakashima N; Tomoda Y; Takahashi T
Cancer Res; 1988 Aug; 48(16):4639-45. PubMed ID: 2456145
[TBL] [Abstract][Full Text] [Related]
9. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3.
Thor A; Gorstein F; Ohuchi N; Szpak CA; Johnston WW; Schlom J
J Natl Cancer Inst; 1986 Jun; 76(6):995-1006. PubMed ID: 3520078
[TBL] [Abstract][Full Text] [Related]
10. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types.
Kabawat SE; Bast RC; Welch WR; Knapp RC; Colvin RB
Am J Clin Pathol; 1983 Jan; 79(1):98-104. PubMed ID: 6336888
[TBL] [Abstract][Full Text] [Related]
11. Differential reactivities of carcinoembryonic antigen (CEA) and CEA-related monoclonal and polyclonal antibodies in common epithelial malignancies.
Sheahan K; O'Brien MJ; Burke B; Dervan PA; O'Keane JC; Gottlieb LS; Zamcheck N
Am J Clin Pathol; 1990 Aug; 94(2):157-64. PubMed ID: 1695478
[TBL] [Abstract][Full Text] [Related]
12. S-100 protein in ovarian tumors. A comparative immunohistochemical study of 135 cases.
Lin M; Hanai J; Wada A; Ozaki M; Nasu K; Okamoto S; Matsumoto K
Acta Pathol Jpn; 1991 Mar; 41(3):233-9. PubMed ID: 2068948
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma.
Berezowski K; Stastny JF; Kornstein MJ
Mod Pathol; 1996 Apr; 9(4):426-9. PubMed ID: 8729984
[TBL] [Abstract][Full Text] [Related]
14. Identification of two different surface epitopes of human ovarian epithelial carcinomas by monoclonal antibodies.
Tsuji Y; Suzuki T; Nishiura H; Takemura T; Isojima S
Cancer Res; 1985 May; 45(5):2358-62. PubMed ID: 2580620
[TBL] [Abstract][Full Text] [Related]
15. Ovarian tumors of low malignant potential (borderline tumors): immune morphology and current status.
Neunteufel W; Gitsch G; Schieder K; Kölbl H; Breitenecker G
Anticancer Res; 1989; 9(4):993-7. PubMed ID: 2684001
[TBL] [Abstract][Full Text] [Related]
16. Clinical use of CA 125 and its combination assay with other tumor marker in patients with ovarian carcinoma.
Negishi Y; Furukawa T; Oka T; Sakamoto M; Hirata T; Okabe K; Matayoshi K; Akiya K; Soma H
Gynecol Obstet Invest; 1987; 23(3):200-7. PubMed ID: 3474196
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of serum CA125, CEA, AFP, LDH levels and LDH isoenzymes in patients with ovarian tumors--correlation between tumor markers and histological types of ovarian tumors].
Konishi I; Fujii S; Okamura H; Sakahara H; Endo K; Torizuka K; Suzuki A; Mori T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):827-36. PubMed ID: 2426374
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunoassay of the CA 12 5 antigen in ovarian carcinomas: advantages compared with CA 19-9 and CEA.
Ricolleau G; Chatal JF; Fumoleau P; Kremer M; Douillard JY; Curtet C
Tumour Biol; 1984; 5(3-4):151-9. PubMed ID: 6594738
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical localization of CA 125 antigen in formalin-fixed paraffin sections of ovarian tumors with the use of Pronase.
Shishi J; Ghazizadeh M; Oguro T; Aihara K; Araki T
Am J Clin Pathol; 1986 May; 85(5):595-8. PubMed ID: 3518399
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical and ultrastructural localization of T antigen in ovarian tumors.
Ghazizadeh M; Oguro T; Sasaki Y; Aihara K; Araki T; Springer GF
Am J Clin Pathol; 1990 Mar; 93(3):315-21. PubMed ID: 1689937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
